Literature DB >> 15163869

Cefpodoxime - utility in respiratory tract infections and typhoid fever.

Anju Aggarwal1, Suman Rath.   

Abstract

Cefpodoxime is a oral third generation cephalosporin active against most of gram positive and gram negative bacteria except Pseudomonas, B. fragilis and Entrococcous. Clinical studies have confirmed efficacy of cefpodoxime in acute otitis media, sinusitis and tosillopharyngitis. Twice daily administration and safety profile increases compliance and decreases failure rate. It has a role as switch over therapy from intravenous ceftriaxone in serious respiratory tract infections (RTIs). In areas where common respiratory pathogens show decreased sensitivity to penicillins and macrolides cefpodoxime can be used as empirical first line therapy in respiratory tract infections. It seems to be a promising molecule in pediatric typhoid fever because of its excellent activity against Salmonella species but clinical trials are limited.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163869     DOI: 10.1007/bf02725629

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  21 in total

1.  Interstitial tissue concentrations of cefpodoxime.

Authors:  Ping Liu; Markus Müller; Maria Grant; Alistair I Webb; Bernd Obermann; Hartmut Derendorf
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

Review 2.  Sequential therapy with intravenous and oral cephalosporins.

Authors:  R Janknegt; J W van der Meer
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

3.  Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin.

Authors:  H Portier; P Chavanet; A Waldner-Combernoux; J P Kisterman; P C Grey; F Ichou; C Safran
Journal:  Scand J Infect Dis       Date:  1994

4.  Typhoid Fever.

Authors:  Christopher M. Parry
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 5.  Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.

Authors:  B S Schatz; K T Karavokiros; M A Taeubel; G S Itokazu
Journal:  Ann Pharmacother       Date:  1996-03       Impact factor: 3.154

6.  Cefpodoxime pharmacokinetics in children: effect of food.

Authors:  G L Kearns; S M Abdel-Rahman; R F Jacobs; T G Wells; M T Borin
Journal:  Pediatr Infect Dis J       Date:  1998-09       Impact factor: 2.129

Review 7.  Clinical efficacy of cefpodoxime in respiratory tract infection.

Authors:  Robert Cohen
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

8.  Antimicrobial activity of new antibiotics against bacterial isolates from a community hospital.

Authors:  J W Dyke; D Angones; D Bhakta; G Tenjarla; A Kumar
Journal:  Chemotherapy       Date:  1993 Sep-Oct       Impact factor: 2.544

9.  Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil.

Authors:  J R Hendrickson; D S North
Journal:  Ann Pharmacother       Date:  1995-06       Impact factor: 3.154

10.  A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity.

Authors:  M E Pichichero; P A Margolis
Journal:  Pediatr Infect Dis J       Date:  1991-04       Impact factor: 2.129

View more
  1 in total

1.  The role of Schedule H1 and Red Line campaign in improving antibiotic use in India.

Authors:  Philip Mathew; Shruthi Anna Thomas; Sujith J Chandy
Journal:  J Family Med Prim Care       Date:  2022-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.